| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperphosphatemia | 23 | 2025 | 25 | 8.820 |
Why?
|
| Renal Dialysis | 53 | 2025 | 357 | 8.420 |
Why?
|
| Hyperparathyroidism, Secondary | 35 | 2025 | 73 | 7.920 |
Why?
|
| Renal Insufficiency, Chronic | 35 | 2025 | 269 | 7.690 |
Why?
|
| Kidney Failure, Chronic | 43 | 2025 | 445 | 5.950 |
Why?
|
| Parathyroid Hormone | 50 | 2026 | 233 | 4.680 |
Why?
|
| Ferric Compounds | 14 | 2023 | 41 | 3.910 |
Why?
|
| Sucrose | 13 | 2023 | 63 | 3.820 |
Why?
|
| Vitamin D | 21 | 2025 | 286 | 3.680 |
Why?
|
| Phosphorus | 24 | 2024 | 119 | 3.380 |
Why?
|
| Phosphates | 15 | 2025 | 165 | 3.100 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 15 | 2025 | 25 | 3.060 |
Why?
|
| Ergocalciferols | 15 | 2020 | 38 | 2.940 |
Why?
|
| Vitamin D Deficiency | 11 | 2020 | 119 | 2.770 |
Why?
|
| Calcifediol | 7 | 2025 | 23 | 2.600 |
Why?
|
| Chelating Agents | 11 | 2023 | 68 | 2.440 |
Why?
|
| Bone and Bones | 19 | 2015 | 270 | 2.400 |
Why?
|
| Kidney Diseases | 17 | 2010 | 314 | 2.390 |
Why?
|
| Bone Diseases, Metabolic | 9 | 2018 | 42 | 2.150 |
Why?
|
| Calcium | 35 | 2026 | 1196 | 2.150 |
Why?
|
| Calcitriol | 15 | 2020 | 173 | 2.110 |
Why?
|
| Kidney Transplantation | 14 | 2020 | 939 | 2.060 |
Why?
|
| Lanthanum | 7 | 2023 | 16 | 1.900 |
Why?
|
| Vitamins | 6 | 2016 | 93 | 1.720 |
Why?
|
| Glomerular Filtration Rate | 18 | 2026 | 299 | 1.680 |
Why?
|
| Bone Diseases | 7 | 2020 | 50 | 1.650 |
Why?
|
| Osteoporosis | 8 | 2025 | 135 | 1.580 |
Why?
|
| Bone Density | 18 | 2025 | 248 | 1.550 |
Why?
|
| Fibroblast Growth Factors | 10 | 2026 | 89 | 1.440 |
Why?
|
| beta 2-Microglobulin | 11 | 2008 | 23 | 1.400 |
Why?
|
| Minerals | 3 | 2018 | 21 | 1.200 |
Why?
|
| Humans | 144 | 2026 | 98080 | 1.160 |
Why?
|
| Drug Combinations | 13 | 2023 | 201 | 1.120 |
Why?
|
| Isoquinolines | 3 | 2024 | 58 | 1.100 |
Why?
|
| Sulfonamides | 4 | 2024 | 351 | 1.100 |
Why?
|
| Calcimimetic Agents | 5 | 2024 | 6 | 0.980 |
Why?
|
| Sevelamer | 6 | 2020 | 6 | 0.970 |
Why?
|
| Amyloidosis | 8 | 2008 | 136 | 0.900 |
Why?
|
| Calciphylaxis | 2 | 2016 | 4 | 0.890 |
Why?
|
| Intestinal Absorption | 2 | 2024 | 125 | 0.870 |
Why?
|
| Middle Aged | 60 | 2026 | 29428 | 0.870 |
Why?
|
| Kidney | 11 | 2026 | 1123 | 0.850 |
Why?
|
| Receptors, Calcitriol | 4 | 2016 | 130 | 0.810 |
Why?
|
| Naphthalenes | 5 | 2010 | 43 | 0.790 |
Why?
|
| Male | 71 | 2026 | 47076 | 0.770 |
Why?
|
| Aged | 46 | 2025 | 21758 | 0.760 |
Why?
|
| Calcium Channel Agonists | 5 | 2007 | 13 | 0.720 |
Why?
|
| Female | 69 | 2026 | 51536 | 0.700 |
Why?
|
| Bone Density Conservation Agents | 5 | 2025 | 53 | 0.670 |
Why?
|
| Peritoneal Dialysis | 6 | 2017 | 31 | 0.640 |
Why?
|
| Parathyroidectomy | 3 | 2022 | 87 | 0.640 |
Why?
|
| Bone Resorption | 5 | 2008 | 42 | 0.640 |
Why?
|
| Disease Progression | 11 | 2025 | 1610 | 0.630 |
Why?
|
| Chronic Disease | 14 | 2026 | 985 | 0.630 |
Why?
|
| Biomarkers | 15 | 2024 | 2020 | 0.620 |
Why?
|
| Treatment Outcome | 22 | 2024 | 9711 | 0.620 |
Why?
|
| Kidney Cortex | 2 | 2019 | 30 | 0.620 |
Why?
|
| Intestine, Small | 1 | 2021 | 318 | 0.590 |
Why?
|
| Fractures, Bone | 5 | 2007 | 161 | 0.590 |
Why?
|
| Polyamines | 3 | 2014 | 38 | 0.580 |
Why?
|
| Bone Remodeling | 4 | 2023 | 22 | 0.570 |
Why?
|
| Kidney Tubules | 1 | 2019 | 91 | 0.560 |
Why?
|
| Delayed-Action Preparations | 5 | 2025 | 126 | 0.550 |
Why?
|
| Femoral Neck Fractures | 1 | 2018 | 13 | 0.540 |
Why?
|
| Hypercalcemia | 5 | 2014 | 60 | 0.510 |
Why?
|
| Quality of Life | 3 | 2023 | 1895 | 0.500 |
Why?
|
| Transplant Recipients | 1 | 2018 | 182 | 0.500 |
Why?
|
| Fracture Fixation, Internal | 1 | 2018 | 97 | 0.500 |
Why?
|
| Hyperparathyroidism | 1 | 2016 | 65 | 0.490 |
Why?
|
| Aluminum | 12 | 1995 | 22 | 0.490 |
Why?
|
| Double-Blind Method | 11 | 2024 | 1782 | 0.480 |
Why?
|
| Skull | 9 | 2008 | 278 | 0.470 |
Why?
|
| Adult | 39 | 2026 | 29539 | 0.470 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 1013 | 0.460 |
Why?
|
| Nephrology | 1 | 2016 | 57 | 0.450 |
Why?
|
| Hypoparathyroidism | 2 | 2026 | 30 | 0.440 |
Why?
|
| Calcinosis | 3 | 2013 | 220 | 0.420 |
Why?
|
| Iron | 4 | 2022 | 178 | 0.420 |
Why?
|
| Skin Ulcer | 1 | 2013 | 28 | 0.400 |
Why?
|
| Oxygen | 4 | 2021 | 802 | 0.400 |
Why?
|
| Osteoblasts | 4 | 2001 | 97 | 0.390 |
Why?
|
| Peptides | 4 | 2026 | 669 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2024 | 3606 | 0.380 |
Why?
|
| Time Factors | 16 | 2021 | 5567 | 0.370 |
Why?
|
| Sodium Bicarbonate | 2 | 2023 | 10 | 0.360 |
Why?
|
| Osteoclasts | 4 | 2013 | 36 | 0.350 |
Why?
|
| Osteogenesis | 6 | 2017 | 279 | 0.340 |
Why?
|
| Glycation End Products, Advanced | 3 | 2013 | 12 | 0.340 |
Why?
|
| Calcification, Physiologic | 3 | 2007 | 34 | 0.330 |
Why?
|
| Pain | 1 | 2013 | 416 | 0.330 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 61 | 0.330 |
Why?
|
| Furosemide | 3 | 2019 | 34 | 0.320 |
Why?
|
| Risk Factors | 13 | 2015 | 6233 | 0.310 |
Why?
|
| Alkaline Phosphatase | 6 | 2015 | 129 | 0.310 |
Why?
|
| Creatinine | 4 | 2021 | 313 | 0.300 |
Why?
|
| Oleanolic Acid | 2 | 2019 | 6 | 0.290 |
Why?
|
| Drug Interactions | 2 | 2021 | 239 | 0.290 |
Why?
|
| Inflammation | 3 | 2024 | 1120 | 0.280 |
Why?
|
| Cyclosporine | 3 | 2004 | 241 | 0.280 |
Why?
|
| Pancreas Transplantation | 3 | 2004 | 120 | 0.270 |
Why?
|
| Biopsy | 4 | 2009 | 1224 | 0.260 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 7389 | 0.260 |
Why?
|
| Protein Kinase C | 2 | 1999 | 267 | 0.250 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 304 | 0.250 |
Why?
|
| Pilot Projects | 3 | 2025 | 977 | 0.250 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 387 | 0.240 |
Why?
|
| Administration, Oral | 5 | 2020 | 674 | 0.240 |
Why?
|
| Prognosis | 7 | 2018 | 4116 | 0.240 |
Why?
|
| Hip Fractures | 1 | 2007 | 55 | 0.240 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 802 | 0.240 |
Why?
|
| Interleukin-6 | 3 | 2008 | 282 | 0.240 |
Why?
|
| Renal Insufficiency | 2 | 2024 | 101 | 0.240 |
Why?
|
| Metabolic Diseases | 1 | 2007 | 60 | 0.240 |
Why?
|
| Animals | 32 | 2021 | 28894 | 0.230 |
Why?
|
| Spinal Fractures | 1 | 2007 | 104 | 0.230 |
Why?
|
| Sodium-Hydrogen Exchanger 3 | 2 | 2024 | 33 | 0.230 |
Why?
|
| Retrospective Studies | 7 | 2023 | 10973 | 0.220 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 2013 | 0.220 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 93 | 0.210 |
Why?
|
| Patient Care Bundles | 1 | 2024 | 22 | 0.210 |
Why?
|
| Canada | 3 | 2015 | 211 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2022 | 4823 | 0.200 |
Why?
|
| Carbonates | 1 | 2023 | 5 | 0.200 |
Why?
|
| Hospitalization | 2 | 2007 | 991 | 0.190 |
Why?
|
| Azathioprine | 1 | 2004 | 127 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2037 | 0.190 |
Why?
|
| Kidney Function Tests | 2 | 2026 | 122 | 0.190 |
Why?
|
| Drug Therapy, Combination | 4 | 2025 | 764 | 0.190 |
Why?
|
| Biological Transport | 2 | 2021 | 401 | 0.190 |
Why?
|
| Albuminuria | 2 | 2021 | 53 | 0.190 |
Why?
|
| Tablets | 2 | 2023 | 136 | 0.190 |
Why?
|
| Niacinamide | 2 | 2020 | 105 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2666 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1110 | 0.180 |
Why?
|
| Interleukin-1 | 2 | 2008 | 72 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2019 | 166 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2007 | 1950 | 0.170 |
Why?
|
| Glucose | 2 | 2002 | 704 | 0.170 |
Why?
|
| United States | 10 | 2024 | 8197 | 0.160 |
Why?
|
| Kidney Medulla | 1 | 2021 | 79 | 0.160 |
Why?
|
| Diet | 2 | 2023 | 469 | 0.160 |
Why?
|
| Phosphorus, Dietary | 1 | 2020 | 4 | 0.160 |
Why?
|
| Iron Overload | 1 | 2020 | 8 | 0.160 |
Why?
|
| Cholecalciferol | 1 | 2020 | 37 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1286 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 1994 | 239 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 707 | 0.150 |
Why?
|
| Biomedical Engineering | 1 | 1999 | 21 | 0.150 |
Why?
|
| Bone Substitutes | 1 | 1999 | 15 | 0.140 |
Why?
|
| Anemia | 1 | 2020 | 135 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 811 | 0.140 |
Why?
|
| Cytokines | 4 | 2012 | 889 | 0.140 |
Why?
|
| Absorbable Implants | 1 | 1999 | 38 | 0.140 |
Why?
|
| Mice | 13 | 2017 | 12698 | 0.140 |
Why?
|
| Receptors, Immunologic | 2 | 2013 | 142 | 0.140 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2020 | 143 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1129 | 0.140 |
Why?
|
| Waist Circumference | 1 | 2018 | 26 | 0.140 |
Why?
|
| Bone Regeneration | 1 | 1999 | 71 | 0.140 |
Why?
|
| Russia | 2 | 2015 | 29 | 0.140 |
Why?
|
| Government Regulation | 1 | 2018 | 49 | 0.140 |
Why?
|
| Australia | 2 | 2015 | 125 | 0.140 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 191 | 0.140 |
Why?
|
| Mice, Inbred Strains | 4 | 2008 | 281 | 0.130 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 239 | 0.130 |
Why?
|
| Acid Phosphatase | 3 | 2008 | 28 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2019 | 1995 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2019 | 2585 | 0.130 |
Why?
|
| Surgeons | 1 | 2022 | 325 | 0.130 |
Why?
|
| Body Weight | 1 | 2018 | 455 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2018 | 186 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 337 | 0.130 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2016 | 2 | 0.120 |
Why?
|
| Arthritis, Experimental | 1 | 2017 | 26 | 0.120 |
Why?
|
| Granzymes | 1 | 2017 | 96 | 0.120 |
Why?
|
| International Agencies | 1 | 2016 | 35 | 0.120 |
Why?
|
| Blood Chemical Analysis | 1 | 2016 | 40 | 0.120 |
Why?
|
| Osteocalcin | 3 | 2001 | 25 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2016 | 21 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 64 | 0.120 |
Why?
|
| Organ Culture Techniques | 5 | 2000 | 120 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2784 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2018 | 250 | 0.120 |
Why?
|
| Pain Measurement | 1 | 2018 | 401 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 283 | 0.120 |
Why?
|
| Rats | 11 | 2020 | 4071 | 0.120 |
Why?
|
| Logistic Models | 2 | 2020 | 1275 | 0.120 |
Why?
|
| Immunoassay | 2 | 2016 | 102 | 0.120 |
Why?
|
| Extracorporeal Circulation | 2 | 2013 | 37 | 0.110 |
Why?
|
| Vascular Calcification | 1 | 2016 | 48 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2018 | 911 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2015 | 75 | 0.110 |
Why?
|
| Organ Transplantation | 1 | 1999 | 306 | 0.110 |
Why?
|
| Prostaglandins | 1 | 1995 | 44 | 0.110 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2017 | 189 | 0.110 |
Why?
|
| Incidence | 2 | 2014 | 1779 | 0.110 |
Why?
|
| Uremia | 1 | 1994 | 14 | 0.110 |
Why?
|
| Acidosis, Respiratory | 1 | 1994 | 7 | 0.110 |
Why?
|
| Acidosis | 1 | 1994 | 55 | 0.110 |
Why?
|
| Infarction | 1 | 1994 | 25 | 0.110 |
Why?
|
| Sex Factors | 2 | 2013 | 1138 | 0.110 |
Why?
|
| Hypocalcemia | 1 | 1994 | 43 | 0.110 |
Why?
|
| Parathyroid Glands | 1 | 1994 | 77 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 360 | 0.100 |
Why?
|
| Radiology | 1 | 2017 | 215 | 0.100 |
Why?
|
| Sorption Detoxification | 1 | 2013 | 2 | 0.100 |
Why?
|
| Brain Diseases | 1 | 1994 | 174 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1782 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2001 | 945 | 0.090 |
Why?
|
| Hematologic Tests | 1 | 2012 | 17 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 39 | 0.090 |
Why?
|
| Serum | 1 | 2012 | 26 | 0.090 |
Why?
|
| Serum Amyloid P-Component | 1 | 1992 | 4 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 63 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 200 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2001 | 2855 | 0.090 |
Why?
|
| Phosphate-Binding Proteins | 2 | 2010 | 11 | 0.090 |
Why?
|
| Gene Expression | 3 | 2008 | 1320 | 0.090 |
Why?
|
| Citric Acid | 2 | 2010 | 47 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 164 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1061 | 0.080 |
Why?
|
| Wound Healing | 1 | 2013 | 384 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2020 | 1255 | 0.080 |
Why?
|
| Nanocomposites | 1 | 2010 | 17 | 0.080 |
Why?
|
| Absorptiometry, Photon | 3 | 2010 | 116 | 0.080 |
Why?
|
| Deferoxamine | 2 | 1988 | 19 | 0.080 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2010 | 4 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2010 | 141 | 0.080 |
Why?
|
| Models, Biological | 2 | 2008 | 1807 | 0.080 |
Why?
|
| Bicarbonates | 2 | 2023 | 60 | 0.080 |
Why?
|
| Cell Line | 3 | 2013 | 2483 | 0.080 |
Why?
|
| Global Health | 2 | 2010 | 215 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2013 | 21 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 1991 | 169 | 0.070 |
Why?
|
| Age Factors | 4 | 2020 | 1962 | 0.070 |
Why?
|
| Contraindications | 1 | 2009 | 66 | 0.070 |
Why?
|
| Cell Division | 2 | 2001 | 689 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2012 | 500 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 4025 | 0.070 |
Why?
|
| Neuromuscular Diseases | 1 | 1988 | 26 | 0.070 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 409 | 0.070 |
Why?
|
| Europe | 1 | 2009 | 356 | 0.070 |
Why?
|
| Graft Rejection | 2 | 2006 | 1186 | 0.070 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 4 | 0.070 |
Why?
|
| Receptors, Calcitonin | 1 | 2008 | 4 | 0.070 |
Why?
|
| RANK Ligand | 1 | 2008 | 12 | 0.070 |
Why?
|
| Integrin beta3 | 1 | 2008 | 31 | 0.070 |
Why?
|
| Physical Conditioning, Animal | 1 | 2007 | 19 | 0.070 |
Why?
|
| Proteinuria | 1 | 2008 | 72 | 0.070 |
Why?
|
| Cyclic AMP | 2 | 1999 | 277 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 85 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2008 | 272 | 0.060 |
Why?
|
| Placebos | 1 | 2007 | 209 | 0.060 |
Why?
|
| Morbidity | 1 | 2007 | 162 | 0.060 |
Why?
|
| Blood-Brain Barrier | 1 | 2007 | 86 | 0.060 |
Why?
|
| Animals, Newborn | 3 | 1994 | 524 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 1999 | 679 | 0.060 |
Why?
|
| Myoclonus | 1 | 1986 | 13 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2010 | 578 | 0.060 |
Why?
|
| Patient Selection | 1 | 2010 | 726 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 1999 | 128 | 0.060 |
Why?
|
| Antibodies | 1 | 2008 | 348 | 0.060 |
Why?
|
| Capsules | 1 | 2006 | 39 | 0.060 |
Why?
|
| Alzheimer Disease | 2 | 1991 | 646 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2013 | 529 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 903 | 0.060 |
Why?
|
| Immunosorbent Techniques | 1 | 2005 | 11 | 0.060 |
Why?
|
| Polymers | 2 | 2013 | 225 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 1945 | 0.050 |
Why?
|
| Adolescent | 3 | 2009 | 10080 | 0.050 |
Why?
|
| Radius | 1 | 2004 | 30 | 0.050 |
Why?
|
| Femur Neck | 1 | 2004 | 42 | 0.050 |
Why?
|
| Medication Adherence | 2 | 2017 | 130 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 511 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2006 | 225 | 0.050 |
Why?
|
| Dementia | 1 | 1986 | 226 | 0.050 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2024 | 78 | 0.050 |
Why?
|
| Alkalies | 1 | 2023 | 10 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 523 | 0.050 |
Why?
|
| Seizures | 1 | 1986 | 318 | 0.050 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2003 | 8 | 0.050 |
Why?
|
| Medical Records | 1 | 2004 | 123 | 0.050 |
Why?
|
| Membranes, Artificial | 1 | 2003 | 39 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2004 | 376 | 0.050 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2003 | 23 | 0.050 |
Why?
|
| Joints | 1 | 2003 | 34 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2007 | 416 | 0.050 |
Why?
|
| Comorbidity | 1 | 2007 | 1033 | 0.050 |
Why?
|
| Protein Denaturation | 1 | 2003 | 110 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2010 | 2681 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 467 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2023 | 202 | 0.050 |
Why?
|
| Glucans | 1 | 2002 | 11 | 0.050 |
Why?
|
| Osteomalacia | 1 | 2001 | 13 | 0.040 |
Why?
|
| Calcitonin | 2 | 1992 | 41 | 0.040 |
Why?
|
| Glucuronidase | 2 | 1992 | 24 | 0.040 |
Why?
|
| Diuretics, Osmotic | 1 | 2001 | 2 | 0.040 |
Why?
|
| Anthraquinones | 1 | 2001 | 9 | 0.040 |
Why?
|
| Kinetics | 2 | 2020 | 1476 | 0.040 |
Why?
|
| Mannitol | 1 | 2001 | 49 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2001 | 70 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 376 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2020 | 290 | 0.040 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2000 | 20 | 0.040 |
Why?
|
| Sepharose | 2 | 2013 | 13 | 0.040 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 22 | 0.040 |
Why?
|
| Staurosporine | 1 | 1999 | 34 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 63 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2020 | 304 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 1999 | 1235 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2019 | 16 | 0.040 |
Why?
|
| Polyglycolic Acid | 1 | 1999 | 10 | 0.040 |
Why?
|
| Biopolymers | 1 | 1998 | 29 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 234 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 194 | 0.040 |
Why?
|
| Lactic Acid | 1 | 1999 | 95 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2019 | 218 | 0.030 |
Why?
|
| Hematoma | 1 | 1999 | 106 | 0.030 |
Why?
|
| Renal Circulation | 1 | 2018 | 30 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1996 | 300 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1815 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 1998 | 135 | 0.030 |
Why?
|
| Reference Values | 1 | 2019 | 608 | 0.030 |
Why?
|
| Potassium Channels | 1 | 2000 | 349 | 0.030 |
Why?
|
| Stroke | 1 | 2007 | 1154 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2000 | 370 | 0.030 |
Why?
|
| Spin Labels | 1 | 2018 | 107 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 153 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1012 | 0.030 |
Why?
|
| Steroids | 1 | 1998 | 168 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2000 | 2063 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 642 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 356 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1996 | 245 | 0.030 |
Why?
|
| Prostaglandin Antagonists | 1 | 1995 | 7 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 50 | 0.030 |
Why?
|
| Indomethacin | 1 | 1995 | 58 | 0.030 |
Why?
|
| Radiography | 2 | 1998 | 764 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 66 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1994 | 94 | 0.030 |
Why?
|
| Culture Media | 1 | 1994 | 138 | 0.030 |
Why?
|
| Ion Transport | 1 | 1994 | 86 | 0.030 |
Why?
|
| Acute Kidney Injury | 2 | 1989 | 372 | 0.030 |
Why?
|
| Amyloid | 1 | 1995 | 104 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 850 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 94 | 0.030 |
Why?
|
| Adsorption | 1 | 2013 | 52 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2014 | 33 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 152 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1751 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 58 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1284 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 47 | 0.030 |
Why?
|
| Sulfones | 1 | 2013 | 48 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 424 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 75 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 488 | 0.020 |
Why?
|
| Maintenance Chemotherapy | 1 | 2014 | 96 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1993 | 33 | 0.020 |
Why?
|
| Constipation | 1 | 2014 | 68 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 166 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 151 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 194 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 418 | 0.020 |
Why?
|
| Diarrhea | 1 | 2014 | 180 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1302 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 1994 | 239 | 0.020 |
Why?
|
| Neurons | 2 | 2000 | 1619 | 0.020 |
Why?
|
| Blood Donors | 1 | 2012 | 24 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 425 | 0.020 |
Why?
|
| Hip | 1 | 1992 | 18 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 1999 | 873 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1992 | 212 | 0.020 |
Why?
|
| Shoulder | 1 | 1992 | 44 | 0.020 |
Why?
|
| Rabbits | 2 | 2010 | 581 | 0.020 |
Why?
|
| Chlorides | 2 | 2002 | 102 | 0.020 |
Why?
|
| Behavior, Animal | 2 | 2007 | 398 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1999 | 3212 | 0.020 |
Why?
|
| Lysosomes | 1 | 1992 | 126 | 0.020 |
Why?
|
| Hand | 1 | 1992 | 143 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 801 | 0.020 |
Why?
|
| Absorption | 2 | 2002 | 26 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2010 | 16 | 0.020 |
Why?
|
| Durapatite | 1 | 2010 | 36 | 0.020 |
Why?
|
| Materials Testing | 1 | 2010 | 96 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1992 | 480 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 40 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1554 | 0.020 |
Why?
|
| Electroencephalography | 1 | 1994 | 789 | 0.020 |
Why?
|
| DNA | 2 | 1993 | 1274 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3598 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2010 | 204 | 0.020 |
Why?
|
| Body Burden | 1 | 1988 | 10 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 263 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 1491 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1990 | 516 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 18 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2007 | 28 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 1988 | 93 | 0.020 |
Why?
|
| Proteins | 1 | 1993 | 804 | 0.020 |
Why?
|
| Capillaries | 1 | 2007 | 86 | 0.020 |
Why?
|
| Brain Edema | 1 | 2007 | 55 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2007 | 58 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2007 | 199 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2007 | 69 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 839 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 2002 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1527 | 0.020 |
Why?
|
| Medicare | 1 | 2010 | 467 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 780 | 0.010 |
Why?
|
| Fluorides | 1 | 1985 | 13 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 889 | 0.010 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2005 | 14 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 2638 | 0.010 |
Why?
|
| Movement | 1 | 2007 | 313 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1988 | 365 | 0.010 |
Why?
|
| Sterilization | 1 | 2005 | 6 | 0.010 |
Why?
|
| Drug Stability | 1 | 2005 | 48 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 87 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1989 | 508 | 0.010 |
Why?
|
| Titrimetry | 1 | 2003 | 14 | 0.010 |
Why?
|
| RNA | 1 | 2007 | 595 | 0.010 |
Why?
|
| Blood | 1 | 2002 | 68 | 0.010 |
Why?
|
| Peritoneum | 1 | 2002 | 52 | 0.010 |
Why?
|
| Aluminum Compounds | 1 | 1982 | 6 | 0.010 |
Why?
|
| Urine | 1 | 2002 | 91 | 0.010 |
Why?
|
| Sodium | 1 | 2002 | 330 | 0.010 |
Why?
|
| Charybdotoxin | 1 | 2000 | 8 | 0.010 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2000 | 5 | 0.010 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2000 | 11 | 0.010 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2000 | 14 | 0.010 |
Why?
|
| Haplorhini | 1 | 2000 | 77 | 0.010 |
Why?
|
| Protein Structure, Quaternary | 1 | 2000 | 105 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 306 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2000 | 384 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 7507 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 581 | 0.010 |
Why?
|
| Epitopes | 1 | 2000 | 258 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1979 | 77 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2000 | 406 | 0.010 |
Why?
|
| Choristoma | 1 | 1998 | 59 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 1998 | 63 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 90 | 0.010 |
Why?
|
| Fetus | 1 | 1979 | 237 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1998 | 127 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 2000 | 318 | 0.010 |
Why?
|
| Insulin | 1 | 2002 | 1225 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 993 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2005 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 911 | 0.010 |
Why?
|
| Cations, Monovalent | 1 | 1995 | 7 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1995 | 34 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 2896 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1998 | 1026 | 0.010 |
Why?
|
| Surface Properties | 1 | 1995 | 129 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 922 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1995 | 191 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 1995 | 14 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1995 | 15 | 0.010 |
Why?
|
| Citrates | 1 | 1995 | 28 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1995 | 90 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1995 | 82 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 889 | 0.010 |
Why?
|
| Prevalence | 1 | 1998 | 1384 | 0.010 |
Why?
|
| Water Supply | 2 | 1985 | 65 | 0.010 |
Why?
|
| Child | 1 | 2004 | 7681 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1995 | 486 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1989 | 64 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1995 | 2529 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1988 | 70 | 0.000 |
Why?
|
| Pregnancy | 2 | 1988 | 3244 | 0.000 |
Why?
|
| Computers | 1 | 1985 | 102 | 0.000 |
Why?
|
| Binding Sites | 1 | 1985 | 1159 | 0.000 |
Why?
|
| Avoidance Learning | 1 | 1982 | 23 | 0.000 |
Why?
|
| Extinction, Psychological | 1 | 1982 | 22 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1982 | 161 | 0.000 |
Why?
|
| Brain | 2 | 1985 | 2430 | 0.000 |
Why?
|
| Michigan | 1 | 1981 | 59 | 0.000 |
Why?
|
| Motor Skills | 1 | 1982 | 81 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1981 | 110 | 0.000 |
Why?
|
| Dogs | 1 | 1981 | 639 | 0.000 |
Why?
|
| Motor Activity | 1 | 1982 | 328 | 0.000 |
Why?
|
| Teratogens | 1 | 1979 | 11 | 0.000 |
Why?
|
| Fetal Death | 1 | 1979 | 55 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1979 | 317 | 0.000 |
Why?
|
| Neutron Activation Analysis | 1 | 1978 | 2 | 0.000 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1978 | 11 | 0.000 |
Why?
|
| Gestational Age | 1 | 1979 | 340 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1978 | 484 | 0.000 |
Why?
|